Sareum Holdings PLC SAR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX31.00
- Day Range
- GBX29.25–31.00
- 52-Week Range
- GBX9.50–40.00
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 139.73M
- Market Cap
- GBX4.28B
- Volume/Avg
- 846,165 / 289,239
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.sareum.com
Valuation
|
Metric
|
SAR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 63.97 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SAR
Financial Strength
|
Metric
|
SAR
|
|---|---|
Quick Ratio | 1.59 |
Current Ratio | 1.59 |
Interest Coverage | — |
Quick Ratio
SAR
Profitability
|
Metric
|
SAR
|
|---|---|
Return on Assets (Normalized) | −83.73% |
Return on Equity (Normalized) | −155.06% |
Return on Invested Capital (Normalized) | −133.70% |
Return on Assets
SAR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Jk&%#K | LOCK|?$jJ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?VqLnXS | LOCK|zd!cM | $76B | |||
| Moderna Inc
MRNA
| LOCK|ZV<!!> | LOCK|@BH | $75B | |||
| argenx SE ADR
ARGX
| LOCK|QqPH<& | LOCK|%JT | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!CvdW^s | LOCK|>f | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?pVLM&S | LOCK|#@>< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pm>!@$& | LOCK|@nX&v | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|dGd!x<Y | LOCK|r? | $24B | |||
| Incyte Corp
INCY
| LOCK|%Zp$p$h | LOCK|?< | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#<DgZV | LOCK|Xb | $15B |
United States